Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse
 over time, but how quickly it progresses varies a lot from person to person. Some symptoms of
 PD are tremors, stiffness, and slowness of movement. This study will assess how safe and
 effective ABBV-951 is in adult participants with PD. Adverse events and change in disease
 activity is evaluated.

 ABBV-951 is an investigational (unapproved) drug containing levodopa/carbidopa (LD/CD) given
 as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants
 with advanced PD and who have completed M15-736 study will be enrolled. Approximately 130
 participants will be enrolled in the study in approximately 80 sites in the United States and
 Australia.

 Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of
 ABBV-951 for 96 weeks.

 There may be higher treatment burden for participants in this trial compared to their
 standard of care. Participants will attend regular visits during the course of the study at a
 hospital or clinic. The effect of the treatment will be checked by medical and remote
 telephone assessments, blood tests, checking for side effects, and completing questionnaires.
Inclusion Criteria:

 -  Completion of the parent study, Study M15-736.

 Exclusion Criteria:

 -  Participant considered by the investigator to be an unsuitable candidate to receive
 ABBV-951 for any reason.